Skin cancer

U.S. Dermatology Partners Announces the Opening of Greenville, Texas Office

Retrieved on: 
Wednesday, February 14, 2024
Skin cancer, Acne, Psoriasis, Certification, Dermatology, World War II, Life, History, Medal, Patient, Audie, Dermatitis, Partner, Hospital

GREENVILLE, Texas, Feb. 14, 2024 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its newest office location in Greenville, Texas. The Greenville location is the latest addition to the U.S. Dermatology Partners' Outreach Program which is dedicated to serving the healthcare needs of rural and underserved communities. The organization aims to increase access to professional dermatologic care in rural areas by introducing over 30 new locations across eight states. These new offices, including the Greenville location, will offer patients easier and more convenient access to much-needed care. Beginning February 14th, the office will extend convenient access to dermatology and skin cancer treatments for patients in Hunt County. The new facility will provide care for various dermatologic conditions, including acne, psoriasis, eczema, and skin cancer.

Key Points: 
  • GREENVILLE, Texas, Feb. 14, 2024 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its newest office location in Greenville, Texas.
  • The Greenville location is the latest addition to the U.S. Dermatology Partners' Outreach Program which is dedicated to serving the healthcare needs of rural and underserved communities.
  • Beginning February 14th, the office will extend convenient access to dermatology and skin cancer treatments for patients in Hunt County.
  • Today's announcement builds on U.S. Dermatology Partners' recent openings of offices in Alva, Oklahoma, Kaufman, Texas, and Peoria, Arizona.

Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery

Retrieved on: 
Tuesday, February 13, 2024
SAN, Skin cancer, Senior, Physician, Cancer, Infection, Metastasis, Risk, Lymph node, Mayo Clinic, DSM-IV codes, Patient, United, Survival, Disease, Bleeding, DGX, Lymph, Melanoma, Medical imaging

SECAUCUS, N.J., and SAN DIEGO, Feb. 13, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced the launch of MelaNodal Predict™, a highly advanced predictive gene expression test to help personalize treatment decisions for patients with melanoma, the deadliest form of skin cancer and one of the most common cancers in the United States.1 Dermatologists and other providers nationwide may begin ordering the test today from Quest Diagnostics, as well as through Dermpath Diagnostics, Quest's subspecialty pathology business.

Key Points: 
  • MelaNodal Predict is a lab-developed test validated by Quest Diagnostics and based on technology developed by SkylineDx, an oncology biotechnology company, alongside Mayo Clinic.
  • MelaNodal Predict examines a patient's original diagnostic tumor biopsy and applies an algorithm to help providers identify patients with a low or high risk of nodal metastasis (melanoma that has spread to the lymph nodes).
  • This insight may help providers identify patients that could, with less risk, avoid a potentially unnecessary, expensive and invasive surgery called a sentinel lymph node biopsy (SLNB).
  • The MelaNodal Predict test's results will help physicians identify their patient's risk of metastasis to assist in individualizing surgical decisions and patient management plans."

U.S. Dermatology Partners Announces the Opening of Alva, Oklahoma Office

Retrieved on: 
Monday, February 12, 2024
Skin cancer, Psoriasis, Acne, Dermatology, Land Run of 1893, Public key certificate, OK, Natural history, Alva, Oklahoma, Northwestern Oklahoma State University, Patient, Dermatitis, Partner, Hospital

ALVA, Okla., Feb. 12, 2024 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its newest office location in Alva, Oklahoma. This new location is the latest addition to the organization's Outreach Program, which is committed to serving rural and underserved communities. To improve access to professional dermatologic care in rural areas, U.S. Dermatology Partners is launching more than 30 new locations across eight states. These new offices, including the Alva location, will provide patients with more convenient access to the care they need and deserve. Beginning February 12th, the office will extend convenient access to dermatology and skin cancer treatments for patients in Woods County. The new facility will provide care for various dermatologic conditions, including acne, psoriasis, eczema, and skin cancer.

Key Points: 
  • U.S. Dermatology Partners expands access to dermatology care to patients in Woods County with the opening of the organization's newest office location.
  • ALVA, Okla., Feb. 12, 2024 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its newest office location in Alva, Oklahoma.
  • To improve access to professional dermatologic care in rural areas, U.S. Dermatology Partners is launching more than 30 new locations across eight states.
  • Beginning February 12th, the office will extend convenient access to dermatology and skin cancer treatments for patients in Woods County.

NDRI Announces Organ Procurement Organization Partnerships and Program Manager for the Somatic Mosaicism across Human Tissues (SMaHT) Network

Retrieved on: 
Wednesday, February 7, 2024
Research, Surgery, Hospitals, Genetics, Biotechnology, Health, Pharmaceutical, General Health, Science, Partnership, AACR, Skin cancer, Mosaic, Hospital, Gift, Maryland School, Genetic variation, Johns Hopkins, Wright State University, ELSI, OPO, MFS, Disease, Tissue, TPC, Bangladesh Technical Education Board, Doctor of Philosophy, University, CPTC, Network, NDRI, Ethics, Pharmaceutical industry

The National Disease Research Interchange (NDRI) is pleased to announce its recovery network and program manager for the Somatic Mosaicism across Human Tissues (SMaHT) Tissue Procurement Center.

Key Points: 
  • The National Disease Research Interchange (NDRI) is pleased to announce its recovery network and program manager for the Somatic Mosaicism across Human Tissues (SMaHT) Tissue Procurement Center.
  • The SMaHT Network is an NIH Common Fund initiative that will provide the first comprehensive public resource for analyzing genetic variation due to somatic mosaicism in human tissues from all developmental layers in the human body.
  • NDRI, in collaboration with the University of Maryland School of Medicine and Johns Hopkins All Children’s Hospital, serve as the Tissue Procurement Center (TPC) for the SMaHT Network.
  • NDRI’s Organ Procurement Organization (OPO) partnerships for the SMaHT Network will include the Gift of Life Donor Program (Philadelphia, PA), ConnectLife (Williamsville, NY), and LifeGift (Houston, TX).

Prevencio and Emory Winship Cancer Institute AI-driven HART CVE Test Data Predicts Risk of Adverse Cardiovascular Effects Associated with Prostate Cancer Therapy

Retrieved on: 
Wednesday, February 7, 2024
Software, Research, Radiology, Oncology, Technology, Artificial Intelligence, Health Technology, Clinical Trials, Science, Cardiology, Other Science, Health, Skin cancer, Prostate cancer, ADT, American Cancer Society, Arrest, AUC, Patient, Diagnosis, Radiation, CVE, Control, Risk, Radiation therapy, Assistant professor, Stroke, Artificial intelligence

Researchers and clinicians from Emory Winship Cancer Institute collaborated to test their prostate cancer population.

Key Points: 
  • Researchers and clinicians from Emory Winship Cancer Institute collaborated to test their prostate cancer population.
  • “With cancer patients living longer, understanding the adverse cardiac effects due to cancer treatments, such as androgen deprivation therapy (ADT), is critical,” said Sagar Anil Patel, M.D., Assistant Professor, Department of Radiation Oncology and member of the Cancer and Control Research Program at Emory Winship Cancer Institute.
  • “It is rewarding to work with Dr. Patel and his team at Emory Winship Cancer Institute to demonstrate HART CVE’s usefulness in monitoring their prostate cancer patients.”
    This data adds to Prevencio’s previous HART CVE risk scoring collaboration with Memorial Sloan Kettering on lung radiation cancer patients.
  • Prostate cancer is the second most common cancer in men in the U.S., after skin cancer.

AMERICAN ACADEMY OF DERMATOLOGY SURVEY SHOWS SUN PROTECTION LACKING IN WINTER

Retrieved on: 
Tuesday, February 6, 2024
UPF, Skin cancer, Melanoma, SPF, Mayo Clinic, Clothing, UV, FAAD, MD, Exercise, Sand, American Academy, Skin, Human, Perspiration, Water, Neck, AAD, Risk, Snow, Sport, Cancer, Face, Cosmetics

ROSEMONT, Ill., Feb. 6, 2024 /PRNewswire/ -- A recent American Academy of Dermatology survey1 revealed that nearly one in five adults are not aware that you can get sunburned during the winter, and even fewer protect themselves from the sun before common outdoor activities in cold weather.

Key Points: 
  • According to the survey, one in seven Americans are unaware that the sun's UV rays are reflected by snow, water, and sand.
  • "Many people don't realize that you need to use sun protection in the winter," said Dawn Davis, MD, FAAD, a board-certified dermatologist and professor of dermatology at Mayo Clinic Rochester.
  • Only 13% of Americans plan to use sun protection when going for walks or hikes in cold weather.
  • "Sun protection is vitally important because ultraviolet (UV) rays are always present, regardless of the season or time of day," said Dr. Davis.

Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements

Retrieved on: 
Tuesday, February 6, 2024
Skin cancer, COVID-19, Inflammation, Pneumonia, Immune system, SRT, Patient, BOCA, Dermatology, COVID, Rheumatoid arthritis, Radiation, Keloid, Poaceae, Physician, Malignancy, DRS, Radiation therapy, Education, Skin, Health, Medical imaging

BOCA RATON, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces a new multi-faceted collaboration with CureRays, a radiation oncology specialist organization based in Atlanta and Grass Valley, Calif. 

Key Points: 
  • Under the collaboration, CureRays will provide Sensus’ dermatology customers with oversight and supervision to assure patient safety, quality, reliability of outcomes and conformance with regulatory requirements, in particular in states where regulations covering the use of ionizing radiation have been tightened.
  • In addition, CureRays will research new indications for Sensus’ superficial radiotherapy (SRT and IG-SRT), including inflammatory diseases.
  • We were anxious to help stem fatalities in any way we could, and we’ve been impressed with their commitment to patient care.
  • My goal is also to help further enhance patient selection against the risks and benefits of radiotherapy.”

U.S. Dermatology Partners Announces the Opening of Kaufman, Texas Office

Retrieved on: 
Tuesday, February 6, 2024
Skin cancer, Dermatitis, Patient, Psoriasis, Veterans Memorial Park, Dermatology, Partner, Public key certificate, Acne, Hospital

KAUFMAN, Texas, Feb. 6, 2024 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its newest office location in Kaufman, Texas. This new location is the latest addition to the organization's Outreach Program, which is committed to serving rural and underserved communities. To improve access to professional dermatologic care in rural areas, U.S. Dermatology Partners is launching more than 30 new locations across eight states. These new offices, including the Kaufman location, will provide patients with more convenient access to the care they need and deserve. Beginning February 6th, the office will extend convenient access to dermatology and skin cancer treatments for patients in Kaufman County. The new facility will provide comprehensive care for various dermatologic conditions, including acne, psoriasis, eczema, and skin cancer.

Key Points: 
  • U.S. Dermatology Partners expands access to dermatology care to patients in Kaufman County with the opening of the organization's newest office location.
  • KAUFMAN, Texas, Feb. 6, 2024 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its newest office location in Kaufman, Texas.
  • To improve access to professional dermatologic care in rural areas, U.S. Dermatology Partners is launching more than 30 new locations across eight states.
  • Beginning February 6th, the office will extend convenient access to dermatology and skin cancer treatments for patients in Kaufman County.

Slone Partners Places Dan Latore as CEO at Red Door Community

Retrieved on: 
Thursday, February 1, 2024
Skin Cancer Foundation, Skin cancer, Sports Illustrated, Knowledge, Senior, Research, People (magazine), FREE, Communication, Sport, Bachelor, Social impact, Account executive, Paramount Streaming, Hope, Education, Empowerment, Rutgers University, Cancer, Health, Nonprofit organization, Management

SOUTH RIDING, Va., Feb. 1, 2024 /PRNewswire-PRWeb/ -- Slone Partners, a nationwide executive search firm for life sciences, healthcare, and cybersecurity organizations, has announced the placement of Dan Latore as Chief Executive Officer (CEO) at Red Door Community, a New York City-based nonprofit organization dedicated to creating a welcoming community of FREE cancer support to bring knowledge, hope, and empowerment to anyone and everyone impacted by cancer.

Key Points: 
  • "Dan Latore is exceptionally devoted to his profession and will be a tremendously valuable addition to the leadership team at Red Door Community," said Bridget Burke, Slone Partners' Senior Vice President & Practice Leader, Healthcare, Nonprofits & Social Impact.
  • "He is exceptionally devoted to his profession and will be a tremendously valuable addition to the leadership team at Red Door Community."
  • "We are thrilled to welcome Dan aboard at a very exciting time in Red Door's evolution," said John DiGiovanni , Chair of the Board of Directors at Red Door Community.
  • "It is with great confidence that I am stepping down as CEO knowing Dan will be the next CEO to lead our organization moving forward," said Lily Safani , Red Door Community's outgoing CEO.

FDA Clearance Granted for First AI-Powered Medical Device to Detect All Three Common Skin Cancers (Melanoma, Basal Cell Carcinoma and Squamous Cell Carcinoma)

Retrieved on: 
Wednesday, January 17, 2024
Technology, FDA, Health, Artificial Intelligence, Practice Management, Research, Medical Devices, Software, Hospitals, Hardware, Science, Clinical Trials, Nursing, Medical Supplies, Dermatology, Patient, Melanoma, Skin, Multimedia, E pluribus unum, Skin cancer, Intelligence, ESS, Medicine, Cancer, Algorithm, Mayo Clinic, Sale, Clinical professor, Disease, EV, Point-of-care testing, Physician, Systematic review, News, Moles, Cochrane Library, Medical imaging

Better identifying skin cancer in a primary care setting is designed to accelerate patient access to necessary care.

Key Points: 
  • Better identifying skin cancer in a primary care setting is designed to accelerate patient access to necessary care.
  • The good news is that 99 percent of skin cancers, including the most deadly form, melanoma, are curable if detected early.
  • The company has conducted 13 clinical studies in the last decade, six of which provided the principal support for FDA clearance.
  • Clinical Utility of an Elastic Scattering Spectroscopy Device in Assisting Primary Care Physician’s Detection of Skin Cancers.